News Column

Recent Studies from University of Bonn Add New Data to Pharmacy and Pharmaceutical Sciences

May 29, 2014



By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting originating from Bonn, Germany, by NewsRx correspondents, research stated, "The clinically approved oncogenic BRAF inhibitor PLX4032 (vemurafenib) was shown to be a substrate of the ATP-binding cassette (ABC) transporter ABCB1. Here, we compared PLX4032 and its structurally closely related precursor compound PLX4720 for their interference with ABCB1 and the ABCB1-mediated compound transport using docking and cell culture experiments."

Our news editors obtained a quote from the research from the University of Bonn, "For the docking study of PLX4032 and PLX4720 with ABCB1, we analysed binding of both compounds to mouse Abcb1a and to human ABCB1 using a homology model of human ABCB1 based on the 3D structure of Abcb1a. Naturally ABCB1 expressing cells including V600E BRAF-mutated and BRAF wild-type melanoma cells and cells transduced with a lentiviral vector encoding for ABCB1 were used as cell culture models. ABCB1 expression and function were studied by the use of fluorescent and cytotoxic ABCB1 substrates in combination with ABCB1 inhibitors. Docking experiments predicted PLX4032 to interact stronger with ABCB1 than PLX4720. Experimental studies using different cellular models and structurally different ABCB1 substrates confirmed that PLX4032 interfered stronger with ABCB1 function than PLX4720. For example, PLX4032 (20 mu M) induced a 4-fold enhanced rhodamine 123 accumulation compared to PLX4720 (20 mu M) in ABCB1-transduced UKF-NB-3 cells and reduced the IC50 for the cytotoxic ABCB1 substrate vincristine in this model by 21-fold in contrast to a 9-fold decrease induced by PLX4720. PLX4032 exerted stronger effects on ABCB1-mediated drug transport than PLX4720."

According to the news editors, the research concluded: "This indicates that small changes in a molecule can substantially modify its interaction with ABCB1, a promiscuous transporter that transports structurally different compounds."

For more information on this research see: Differential Effects of the Oncogenic BRAF Inhibitor PLX4032 (Vemurafenib) and its Progenitor PLX4720 on ABCB1 Function. Journal of Pharmacy and Pharmaceutical Sciences, 2014;17(1):154-168. Journal of Pharmacy and Pharmaceutical Sciences can be contacted at: Canadian Soc Pharmaceutical Sciences, 3118 Dentistry-Pharmacy Centre Univ Alberta Campus, Edmonton, Alberta T6G2N8, Canada (see also Drugs and Therapies).

The news editors report that additional information may be obtained by contacting M. Michaelis, University of Bonn, Inst Pharmacol & Toxicol, Biomed Center BMZ, Bonn, Germany. Additional authors for this research include F. Rothweiler, T. Nerreter, M. van Rikxoort, M. Sharifi, M. Wiese, T. Ghafourian and J. Cinatl.

Keywords for this news article include: Bonn, Biotechnology, Europe, Germany, Gene Therapy, Bioengineering, Drugs and Therapies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters